HUE028331T2 - N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás - Google Patents
N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás Download PDFInfo
- Publication number
- HUE028331T2 HUE028331T2 HUE03798156A HUE03798156A HUE028331T2 HU E028331 T2 HUE028331 T2 HU E028331T2 HU E03798156 A HUE03798156 A HU E03798156A HU E03798156 A HUE03798156 A HU E03798156A HU E028331 T2 HUE028331 T2 HU E028331T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- ser
- human
- leu
- peptide
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (7)
- hidÎ-CSONKOO' ß-AMILÖÖ> ELLENI MÖN0KLCE4ÁLÍI ELLEN ANYAGI, KÉSEÍTMENY, ELJÁRÁS ÈS ALKALMAZÁS Szabadalmi 8gé»y|m»tí>k t, Mooekletiâlis: dlenaayag, amelÿ specitikussn Mispmn aa ABlLMtérje <3teH-nàl BACH-l-gyel fortém hasítása «tán kapott Aßll-x pepiidet egyéb Akfoiragpiensékre adott kermzírsatóo. aéïfâl, ahol a ímmokkieáMS ellenanyag specifikusán folisæen «à {EsàdsïeiàzjLÎ hasítási hely «IsS 5-7 batöáte amiaosavät, mm a Seq Mbfo,:l és Saq là. No.;2 szerinti szekvenciát, vagy az ß-sBekreta;;Π hasítási hs% első 5-? sgéréradátii mmaôsavâh mm a Seq M bio.:3 és Seq U Hfofo szedné szekvenciát. Ί M L Igénypetst saersaÁ mpaokíoösiis ellenanyag, azzal jelkstezw, hogy áz Api 1A pepiid emberi Api 1-40.
- 3. Ás L vagy 2. igénypont szerinti ellenanyag, amely kim«talítstő modo« címkézett. 4, A 3. igénypont szenmi ellenanyag, ahol a ksnutatható eímfce mdioaktív jelölés, enzi®}efolé§, laaakesssceas jelölés vagy ttuoreszeens jelölés,
- 5, Az Id/igëaypostok bâiftïdyike szerinti eUeaaayag»-aaa^ly .feordözétt immoinikáli.
- 6. As I -S. igétrypontok hàmfoiyike szerinti ellenanyag, assoiym à Belgiaa Coordinated Collections of Mfcrootganteaas-nál 2003. angosztus \9'φ& rendié LMBP 5;#6CB ás LMBP 5897CB letéti szám«» letétbe helyeselt jMPRD/feAßl 3/1 ás MJPRDdxÄßil/2 htbndomaseitek Mpresszalsmk. %. A 20()2. augusztus IR-en a Belgian Coordinated Collections of Microorgamsms-ml rendre LMBP 5896CB és LMBP 5897CB: letéti számon létéibe helyezett I&JFRD/feApil/l és JMPRD/hAßU/2 hilmdómasejtek
- 8, Isununvizsgáiati módszer mtniabsö AFMshárje Clitl Bőéi BACEd-gyel történt hasítása után kapott Aßii-x pepiM meghatárosására vagy kimutatására, amely eljárás magában foglalja a minta érintkezietését 1-3. Igénypontok bármelyike szerinti, AßlLx pepiid elleni ellenanyaggal és annak meghatározását, bogf képződött' e komplex az ellenanyag; és az Aßl l-x peptid közöm % B||áíás szövetmintában AFF-febérjs Olull-aéi BACiE-l-gyél tânèni háshásá «ián kapott Aßl l-x pepttl! jelenlétének kimutatására, amely eljárás- magában foglalja a kővetkezőket: alahy iésfoffoi származó szőveímlma. édntkeztetése képalkotó eljárásban hatásos mennyiségű, 3. vagy 4. igénypont szériöít, kitntdathfoban uiíttkézeít ellenanyaggal, ás «..címke kknutaiása, ezáltal a szőveímmtáfean az Api 1 -x pepiid jeksiétáuek mégáüapitása. 19. A % igénypontszerinti eljárás, ahol a tómwiaih»tó «iodes címkézett ellenanyagi« a 6. igénypont szénné, legalább egyik bsbridómare.·t espresszálja
- 11. BÍíms tesífoiyssdékOiiíííábsn APF-Míé# Gla'l 1-náJ BACE-l-gye! tósléni hasítása mán kapott Aß| 1-X pepiid jelenlétének kímaiatására, aœ# «yáras magában fdgiaí|a a követelőket: alanjr testiből .gteató i«stíöl>nddkfp5«ía: árimkeztetáss képalkotó eljárásban hatásos mentsyiségá*· 3. vagy 41 igénypom szerinti, kte^^ltósít.stofc^ett4ite»aaya^:al, és scímke kíístitaldsa. ezáltal a testKslyaPokmístában az Mbi-x peptid jólonláténektnegáíainiása. i%. A 11, igénypont szerinti etjárás, almi a Mmoíatbalóa« CiöAégetíi eilemmyágot a ?. igénypont szerinti legalább egy tk éibrklémasejl: exprexszália,
- 13, M Eb, ígésypoPtok básöí&lyíke szeréi« «liena-iyag alkalmazása ß-anbioidbsi kapcsolatos betegség ín vkro diagnoszíszállsáza, 14; Diagnosztikai készítmény, aso# Wtátoaz 1-6. fénypontok bármelyike szcrM ellenanyagot és gyógjAszatilag el'fógadbató hordozót. iS, Ipipmhyjzsgslatra szolgáló készlet jhamiloiddai kapcsolatos betegség: diagrmsztizáiására, amely tanalmaz 2-S. igéoyponiöípbármslyike szénát! eSmaayagot és hordozol sz eilenääiysg szársíéra.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/011062 WO2004029629A1 (en) | 2002-09-27 | 2002-09-27 | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE028331T2 true HUE028331T2 (hu) | 2016-12-28 |
Family
ID=32039081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE03798156A HUE028331T2 (hu) | 2002-09-27 | 2003-09-09 | N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9329189B2 (hu) |
| EP (1) | EP1546734B1 (hu) |
| JP (3) | JP2006513988A (hu) |
| CN (2) | CN101367875B (hu) |
| AU (1) | AU2003266378B2 (hu) |
| CA (1) | CA2498058C (hu) |
| CY (1) | CY1117387T1 (hu) |
| DK (1) | DK1546734T3 (hu) |
| ES (1) | ES2560853T3 (hu) |
| HU (1) | HUE028331T2 (hu) |
| PT (1) | PT1546734E (hu) |
| SI (1) | SI1546734T1 (hu) |
| WO (2) | WO2004029629A1 (hu) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| EA200501524A1 (ru) * | 2003-03-28 | 2006-06-30 | Сентокор, Инк. | Антитела против амилоида, композиции, способы и применения |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| WO2006039470A2 (en) * | 2004-09-29 | 2006-04-13 | Centocor, Inc. | Anti- amyloid antibodies, compositions, methods and uses |
| ES2259270B1 (es) * | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| EP1959996A2 (en) * | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoclonal antibody |
| JP5103466B2 (ja) * | 2006-03-30 | 2012-12-19 | グラクソ グループ リミテッド | アミロイド‐βペプチドに対する抗体 |
| US20100028351A1 (en) * | 2006-06-29 | 2010-02-04 | Marc Mercken | Anti-amyloid antibodies, compositions, methods and uses |
| EP2046833B9 (en) * | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
| ES2529174T3 (es) * | 2007-06-12 | 2015-02-17 | Ac Immune S.A. | Anticuerpos humanizados para amiloide beta |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| BRPI0818623A2 (pt) * | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal |
| AU2008311367B2 (en) * | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| US20100074901A1 (en) * | 2007-10-15 | 2010-03-25 | Marc Hubert Mercken | Human anti-amyloid antibodies, compositions, methods and uses |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2586797A3 (en) * | 2007-11-27 | 2013-07-24 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| CN101463085B (zh) * | 2009-01-16 | 2011-09-14 | 清华大学 | 与A-beta寡聚体特异性结合的基因工程单克隆抗体 |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| CA2828433C (en) * | 2011-03-16 | 2020-08-04 | Probiodrug Ag | Diagnostic antibody assay |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| JP6499079B2 (ja) | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーBioNTech AG | クローディンを発現するガン疾患を処置するための剤 |
| EP3594240B1 (en) | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| KR20170085595A (ko) | 2014-12-10 | 2017-07-24 | 제넨테크, 인크. | 혈뇌 장벽 수용체 항체 및 사용 방법 |
| AU2016353553B2 (en) | 2015-11-09 | 2022-01-20 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
| KR102776187B1 (ko) | 2015-11-09 | 2025-03-07 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체 |
| EP3374381A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF |
| CN109476729A (zh) | 2016-07-18 | 2019-03-15 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| JP7434144B2 (ja) | 2018-02-27 | 2024-02-20 | 株式会社島津製作所 | APP669-xのN末端を特異的に認識する抗体、及び免疫測定法 |
| CN113226283A (zh) | 2018-10-04 | 2021-08-06 | 罗切斯特大学 | 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送 |
| AR117453A1 (es) | 2018-12-20 | 2021-08-04 | Genentech Inc | Fc de anticuerpos modificados y métodos para utilizarlas |
| JP7207517B2 (ja) | 2019-03-01 | 2023-01-18 | 株式会社島津製作所 | App669-711の測定方法、及び測定用キット |
| CN114026109A (zh) | 2019-07-05 | 2022-02-08 | 株式会社岛津制作所 | β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法 |
| KR20230039734A (ko) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | 항-Aβ 항체 |
| CN112540180B (zh) * | 2020-11-06 | 2022-03-29 | 华中科技大学 | 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2025250454A1 (en) | 2024-05-28 | 2025-12-04 | University Of Rochester | Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ337765A (en) * | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| US20020157122A1 (en) * | 2000-10-27 | 2002-10-24 | Wong Philip C. | Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| AU2012286021A1 (en) * | 2011-07-15 | 2014-01-16 | Janssen Pharmaceutica Nv | Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof |
-
2002
- 2002-09-27 WO PCT/EP2002/011062 patent/WO2004029629A1/en not_active Ceased
-
2003
- 2003-09-09 CN CN200810133343XA patent/CN101367875B/zh not_active Expired - Fee Related
- 2003-09-09 ES ES03798156.0T patent/ES2560853T3/es not_active Expired - Lifetime
- 2003-09-09 PT PT37981560T patent/PT1546734E/pt unknown
- 2003-09-09 DK DK03798156.0T patent/DK1546734T3/en active
- 2003-09-09 CA CA2498058A patent/CA2498058C/en not_active Expired - Fee Related
- 2003-09-09 EP EP03798156.0A patent/EP1546734B1/en not_active Expired - Lifetime
- 2003-09-09 AU AU2003266378A patent/AU2003266378B2/en not_active Ceased
- 2003-09-09 JP JP2004538886A patent/JP2006513988A/ja active Pending
- 2003-09-09 SI SI200332460T patent/SI1546734T1/sl unknown
- 2003-09-09 HU HUE03798156A patent/HUE028331T2/hu unknown
- 2003-09-09 CN CNB038231166A patent/CN100418984C/zh not_active Expired - Fee Related
- 2003-09-09 WO PCT/EP2003/010092 patent/WO2004029630A1/en not_active Ceased
- 2003-09-09 US US10/528,928 patent/US9329189B2/en not_active Expired - Fee Related
-
2014
- 2014-06-24 JP JP2014129164A patent/JP6420072B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-11 CY CY20161100112T patent/CY1117387T1/el unknown
- 2016-04-29 US US15/142,075 patent/US9939452B2/en not_active Expired - Fee Related
-
2017
- 2017-03-09 JP JP2017045114A patent/JP2017149719A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003266378B2 (en) | 2010-01-21 |
| CN101367875A (zh) | 2009-02-18 |
| US9329189B2 (en) | 2016-05-03 |
| CA2498058C (en) | 2013-02-12 |
| US9939452B2 (en) | 2018-04-10 |
| CN101367875B (zh) | 2013-06-12 |
| US20060127954A1 (en) | 2006-06-15 |
| CY1117387T1 (el) | 2017-04-26 |
| HK1081647A1 (zh) | 2006-05-19 |
| CN1685236A (zh) | 2005-10-19 |
| JP2006513988A (ja) | 2006-04-27 |
| EP1546734A1 (en) | 2005-06-29 |
| US20170192016A1 (en) | 2017-07-06 |
| ES2560853T3 (es) | 2016-02-23 |
| AU2003266378A1 (en) | 2004-04-19 |
| SI1546734T1 (sl) | 2016-02-29 |
| JP6420072B2 (ja) | 2018-11-07 |
| JP2014208678A (ja) | 2014-11-06 |
| JP2017149719A (ja) | 2017-08-31 |
| WO2004029629A1 (en) | 2004-04-08 |
| WO2004029630A1 (en) | 2004-04-08 |
| PT1546734E (pt) | 2016-03-01 |
| CA2498058A1 (en) | 2004-04-08 |
| DK1546734T3 (en) | 2016-02-08 |
| CN100418984C (zh) | 2008-09-17 |
| EP1546734B1 (en) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1546734T3 (en) | MONOCLONAL ANTIBODIES AGAINST N-11-TRUNCATED AMYLOID BETA, COMPOSITIONS, PROCEDURES AND APPLICATIONS | |
| EP0683234B2 (en) | Antibody against beta-amyloid or their derivative and use thereof | |
| US10208111B2 (en) | Alpha-synuclein antibodies and uses thereof | |
| JP3115606B2 (ja) | βA4ペプチドに特異的なモノクローナル抗体 | |
| US5955317A (en) | Antibodies to β-amyloids or their derivatives and use thereof | |
| JP3553592B2 (ja) | 可溶性β−アミロイド・ペプチドの検出のための方法及び組成物 | |
| EP2189526B1 (en) | Antibody binding specifically to tdp-43 aggregate | |
| US5985581A (en) | Use of presenilin-1 for diagnosis of alzheimers disease | |
| EP0655626A1 (en) | Diagnostic assays for Alzheimer's disease | |
| JP4374316B2 (ja) | β−アミロイドまたはその誘導体に対する抗体およびその用途 | |
| JP2955082B2 (ja) | ヒトカルシトニンのn末端部分を特異的に認識するモノクローナル抗体 | |
| JP4037933B2 (ja) | 抗ヒトカルシトニンモノクローナル抗体 | |
| JP2014520825A (ja) | モノクローナル抗体に対して特異的なβ−アミロイドx−37およびその使用 | |
| HK1081647B (en) | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses | |
| HK1126797A (en) | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses | |
| HK1217107B (en) | Alpha-synuclein antibodies and uses thereof | |
| JPWO1994017197A1 (ja) | β−アミロイドまたはその誘導体に対する抗体およびその用途 |